Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Thomas Eipe
Institutions:
Homi Bhabha National Institute,
Tata Memorial Hospital,
Advanced Centre for Treatment, Research and Education in Cancer
Observed institutions:
JSS Academy of Higher Education and Research,
Homi Bhabha National Institute,
Tata Memorial Hospital,
Advanced Centre for Treatment, Research and Education in Cancer,
JSS College of Pharmacy
ORCID:
0000-0001-9004-1233
Observed ORCID:
0000-0001-9004-1233
OpenAlex ID:
A5088379232
Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: results from the PETAL consortium
2024
·
Jessy Xinyi Han
, Min Jung Koh
, et al.
·
Blood Advances
·
17
PDF
Clinical Utility of Stepwise Bronchoalveolar Lavage Fluid Analysis in Diagnosing and Managing Lung Infiltrates in Leukemia/Lymphoma Patients With Febrile Neutropenia
2024
·
Jayashree Thorat
, Surabhi Bhat
, et al.
·
JCO Global Oncology
·
6
PDF
A Prospective Study to Evaluate the Effect of Therapeutic Drug Monitoring-Based Posaconazole Prophylaxis on Invasive Fungal Infection Rate During Acute Myeloid Leukemia Induction Therapy
2023
·
Mounika Boppana
, Manju Sengar
, et al.
·
Indian Journal of Hematology and Blood Transfusion
·
6
PDF
The current treatment approach to adolescents and young adults with acute lymphoblastic leukemia (AYA-ALL): challenges and considerations
2022
·
Hasmukh Jain
, Akhil Rajendra
, et al.
·
Expert Review of Anticancer Therapy
·
6
Reduced Vitamin D levels and Iron Deficiency Anaemia in Pregnant Women: An Evolving Correlation
2018
·
Roopa Satyanarayan Basutkar
, Thomas Eipe
, et al.
·
Journal of Young Pharmacists
·
6
PDF
Forecasting optimal treatments in relapsed/refractory mature T‐ and NK ‐cell lymphomas: A global PETAL Consortium study
2025
·
Mark N. Sorial
, Jessy Xinyi Han
, et al.
·
British Journal of Haematology
·
5
PDF
Real-World Analysis Evaluating Treatment Eligibility and Outcomes in Patients With AML Receiving Intensive Chemotherapy: Insights From an Underrepresented Population
2025
·
Hasmukh Jain
, Thomas Eipe
, et al.
·
JCO Global Oncology
·
5
Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility
2023
·
Atharva Karulkar
, Ankesh Kumar Jaiswal
, et al.
·
Blood
·
3
PDF
A prospective observational study to compare the efficacy, time toxicity, and cost of conventional 3+7 regimen versus azacitidine + venetoclax (AZA + VEN) as induction therapy in patients with acute myeloid leukemia (AML).
2026
·
Manju Sengar
, Arvind Vaidyanathan
, et al.
·
Journal of Clinical Oncology
·
2
A retrospective observational study to evaluate the reliability of staging and risk stratification of adolescent and adult patients with Hodgkin’s lymphoma registered at the lymphoma clinic of a tertiary cancer center in Western India
2023
·
Ajay Kumar Singh
, Thomas Eipe
, et al.
·
Cancer Research Statistics and Treatment
·
2
Safety and feasibility of outpatient induction with intensive monitoring in AML: pilot study and extension cohort
2026
·
Hasmukh Jain
, Alok Shetty
, et al.
·
Blood Global Hematology
·
1
PDF
Early time-to-relapse as a predictor of survival in mature T-cell/NK-cell lymphomas: Results from the PETAL consortium
2025
·
Mark Sorial
, Kenechukwu Aniagboso
, et al.
·
Blood
·
1
CT-643 An Analysis of Infectious Complications Post-Treatment With Actalycabtagene Autoleucel
2024
·
Hasmukh Jain
, Rohan Verghese
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
1
Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms
2023
·
Min Jung Koh
, Leora Boussi
, et al.
·
Blood
·
1
PDF
Real-World Outcomes with Intensive Chemotherapy in Acute Myeloid Leukemia Patients Deemed “Unfit” for Remission Induction By Landmark Trials' Criteria
2023
·
Thomas Eipe
, Hasmukh Jain
, et al.
·
Blood
·
1
ALL-772: Efficacy of Inotuzumab Ozogamicin When Used as Salvage/Bridging Therapy Prior to CD19-Directed CAR-T Therapy in Relapsed/Refractory B-ALL: A Single-Center Experience
2026
·
Anupa John
, Alok Shetty
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: CT-1231: Impact of Loss of B-Cell Aplasia on Clinical Outcomes Following Talicabtagene Autoleucel in Patients With Relapsed/Refractory B-Cell Malignancies: A Single-Center Real-World Experience
2026
·
Sahitya Rao
, Hasmukh Jain
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
AML-327: Steroid-Associated Toxicities and Survival Outcomes in Acute Promyelocytic Leukemia Treated With ATO/ATRA With or Without Chemotherapy
2026
·
Gautam Pantwalawalkar
, Hasmukh Jain
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
CT-1231: Impact of Loss of B-Cell Aplasia on Clinical Outcomes Following Talicabtagene Autoleucel in Patients With Relapsed/Refractory B-Cell Malignancies: A Single-Center Real-World Experience
2026
·
Sahitya Rao
, Hasmukh Jain
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-327: Steroid-Associated Toxicities and Survival Outcomes in Acute Promyelocytic Leukemia Treated With ATO/ATRA With or Without Chemotherapy
2026
·
Gautam Pantwalawalkar
, Hasmukh Jain
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: ALL-772: Efficacy of Inotuzumab Ozogamicin When Used as Salvage/Bridging Therapy Prior to CD19-Directed CAR-T Therapy in Relapsed/Refractory B-ALL: A Single-Center Experience
2026
·
Anupa John
, Alok Shetty
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
ABCL-570: Early Experience With Glofitamab Plus Polatuzumab Vedotin as Bridging Therapy Prior to CD19-Directed CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma
2026
·
Yash Shah
, Thomas Eipe
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-570: Early Experience With Glofitamab Plus Polatuzumab Vedotin as Bridging Therapy Prior to CD19-Directed CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma
2026
·
Yash Shah
, Thomas Eipe
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Genomic profiling of Burkitt lymphoma in adults: Novel molecular insights and implications for outcomes.
2026
·
Manju Sengar
, Epari Sridhar
, et al.
·
Journal of Clinical Oncology
PDF
Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium
2026
·
Colin J. Thomas
, Min Jung Koh
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
Show more works
View as search
Works count:
40
Citation count:
63
H-index:
5
I10-index:
1
Year
Topic
Type